Related Experiment Video
Updated: Mar 17, 2026
05:24
Teratoma Generation in the Testis Capsule
Published on: November 7, 2011
21.5K
[Testicular malignant Leydig cell tumor: A case report].
Zhonghua Nan Ke Xue = National Journal of Andrology
|July 16, 2016
Summary
Malignant Leydig cell tumors (TMLCT) are rare, aggressive gonadal stromal tumors. Circulating tumor cells (CTCs) show potential for early diagnosis and prognosis in TMLCT.
Area of Science:
- Oncology
- Pathology
- Genitourinary Cancer
Background:
- Testicular malignant Leydig cell tumor (TMLCT) is an exceptionally rare sex-gonad stromal tumor.
- Characterized by high malignancy and a poor prognosis, TMLCT presents diagnostic challenges.
Observation:
- A case study of a 47-year-old male with TMLCT revealed Leydig cell composition with suspected vessel carcinoma embolus.
- Immunohistochemistry confirmed specific tumor markers (α-inhibin, Ki67, CD30, vimentin, EMA, PLAP).
- Circulating tumor cells (CTCs) were detected in peripheral blood, and the patient underwent multiple treatments for metastatic disease.
Findings:
- The study identified key clinicopathological features of TMLCT.
- Detection of circulating tumor cells (CTCs) in peripheral venous blood was achieved.
- The patient experienced disease progression despite chemotherapy and surgical interventions.
Implications:
- TMLCT necessitates further investigation due to its aggressive nature.
- Circulating tumor cells (CTCs) may serve as a valuable biomarker for early diagnosis and prognostic assessment in TMLCT.
- Improved non-invasive diagnostic strategies for TMLCT are crucial.
